Plasma Cannabinoid Concentrations During Dronabinol Pharmacotherapy for Cannabis Dependence

被引:16
|
作者
Milman, Garry [1 ]
Bergamaschi, Mateus M. [1 ]
Lee, Dayong [1 ]
Mendu, Damodara R. [1 ]
Barnes, Allan J. [1 ]
Vandrey, Ryan [2 ]
Huestis, Marilyn A. [1 ]
机构
[1] NIDA, Chem & Drug Metab Sect, Intramural Res Program, Biomed Res Ctr,NIH, Baltimore, MD 21224 USA
[2] Johns Hopkins Bayview Med Ctr, Behav Pharmacol Res Unit, Baltimore, MD USA
基金
美国国家卫生研究院;
关键词
dronabinol; plasma; cannabinoids; smoking; oral administration; ORAL THC; DELTA-9-TETRAHYDROCANNABINOL CONCENTRATIONS; TOBACCO WITHDRAWAL; MARIJUANA; SMOKING; BLOOD; DELTA(9)-TETRAHYDROCANNABINOL; ABSORPTION; THCCOOH; IMPACT;
D O I
10.1097/FTD.0b013e3182a5c446
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background:Recently, high-dose oral synthetic delta-9-tetrahydrocannabinol (THC) was shown to alleviate cannabis withdrawal symptoms. The present data describe cannabinoid pharmacokinetics in chronic, daily cannabis smokers who received high-dose oral THC pharmacotherapy and later a smoked cannabis challenge.Methods:Eleven daily cannabis smokers received 0, 30, 60, or 120 mg/d THC for four 5-day medication sessions, each separated by 9 days of ad libitum cannabis smoking. On the fifth day, participants were challenged with smoking one 5.9% THC cigarette. Plasma collected on the first and fifth days was quantified by two-dimensional gas chromatography mass spectrometer for THC, 11-hydroxy-THC (11-OH-THC), and 11-nor-9-carboxy-THC (THCCOOH). Linear ranges (ng/mL) were 0.5-100 for THC, 1-50 for 11-OH-THC, and 0.5-200 for THCCOOH.Results:During placebo dosing, THC, 11-OH-THC, and THCCOOH concentrations consistently decreased, whereas all cannabinoids increased dose dependently during active dronabinol administration. THC increase over time was not significant after any dose, 11-OH-THC increased significantly during the 60- and 120-mg/d doses, and THCCOOH increased significantly only during the 120-mg/d dose. THC, 11-OH-THC, and THCCOOH concentrations peaked within 0.25 hours after cannabis smoking, except after 120 mg/d THC when THCCOOH peaked 0.5 hours before smoking.Conclusions:The significant withdrawal effects noted during placebo dronabinol administration were supported by significant plasma THC and 11-OH-THC concentration decreases. During active dronabinol dosing, significant dose-dependent increases in THC and 11-OH-THC concentrations support withdrawal symptom suppression. THC concentrations after cannabis smoking were only distinguishable from oral THC doses for 1 hour, too short a period to feasibly identify cannabis relapse. THCCOOH/THC ratios were higher 14 hours after overnight oral dronabinol abstinence but cannot distinguish oral THC dosing from the smoked cannabis intake.
引用
收藏
页码:218 / 224
页数:7
相关论文
共 50 条
  • [31] Comparison of cannabinoid concentrations in oral fluid and whole blood between occasional and regular cannabis smokers prior to and after smoking a cannabis joint
    Fabritius, Marie
    Chtioui, Haithem
    Battistella, Giovanni
    Annoni, Jean-Marie
    Dao, Kim
    Favrat, Bernard
    Fornari, Eleonora
    Lauer, Estelle
    Maeder, Philippe
    Giroud, Christian
    ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2013, 405 (30) : 9791 - 9803
  • [32] Comparison of cannabinoid concentrations in oral fluid and whole blood between occasional and regular cannabis smokers prior to and after smoking a cannabis joint
    Marie Fabritius
    Haithem Chtioui
    Giovanni Battistella
    Jean-Marie Annoni
    Kim Dao
    Bernard Favrat
    Eleonora Fornari
    Estelle Lauer
    Philippe Maeder
    Christian Giroud
    Analytical and Bioanalytical Chemistry, 2013, 405 : 9791 - 9803
  • [33] Urinary cannabinoid levels during nabiximols (Sativex®)-medicated inpatient cannabis withdrawal
    Kevin, Richard C.
    Allsop, David J.
    Lintzeris, Nicholas
    Dunlop, Adrian J.
    Booth, Jessica
    McGregor, Iain S.
    FORENSIC TOXICOLOGY, 2017, 35 (01) : 33 - 44
  • [34] Urinary cannabinoid levels during nabiximols (Sativex®)-medicated inpatient cannabis withdrawal
    Richard C. Kevin
    David J. Allsop
    Nicholas Lintzeris
    Adrian J. Dunlop
    Jessica Booth
    Iain S. McGregor
    Forensic Toxicology, 2017, 35 : 33 - 44
  • [35] Measurement uncertainty revealed: The impacts of Certified Reference Material (CRM) on cannabinoid concentrations in the cannabis testing industry
    Goldman, Stephen
    TALANTA OPEN, 2024, 10
  • [36] Cannabinoid concentrations in spot serum samples 24-48 hours after discontinuation of cannabis smoking
    Skopp, Gisela
    Poetsch, Lucia
    JOURNAL OF ANALYTICAL TOXICOLOGY, 2008, 32 (02) : 160 - 164
  • [37] Evidence for Association Between Polymorphisms in the Cannabinoid Receptor 1 (CNR1) Gene and Cannabis Dependence
    Agrawal, Arpana
    Wetherill, Leah
    Dick, Danielle M.
    Xuei, Xiaoling
    Hinrichs, Anthony
    Hesselbrock, Victor
    Kramer, John
    Nurnberger, John I., Jr.
    Schuckit, Marc
    Bierut, Laura J.
    Edenberg, Howard J.
    Foroud, Tatiana
    AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS, 2009, 150B (05) : 736 - 740
  • [38] Oral fluid/plasma cannabinoid ratios following controlled oral THC and smoked cannabis administration
    Dayong Lee
    Ryan Vandrey
    Garry Milman
    Mateus Bergamaschi
    Damodara R. Mendu
    Jeannie A. Murray
    Allan J. Barnes
    Marilyn A. Huestis
    Analytical and Bioanalytical Chemistry, 2013, 405 : 7269 - 7279
  • [39] Oral fluid/plasma cannabinoid ratios following controlled oral THC and smoked cannabis administration
    Lee, Dayong
    Vandrey, Ryan
    Milman, Garry
    Bergamaschi, Mateus
    Mendu, Damodara R.
    Murray, Jeannie A.
    Barnes, Allan J.
    Huestis, Marilyn A.
    ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2013, 405 (23) : 7269 - 7279
  • [40] Time course of cannabinoid accumulation and chemotype development during the growth of Cannabis sativa L
    D. Pacifico
    F. Miselli
    A. Carboni
    A. Moschella
    G. Mandolino
    Euphytica, 2008, 160 : 231 - 240